IL33 and Alzheimer disease: Interestingly, while the expression levels of type 2 cytokines IL-4, IL-13, and IL-33 and pruritic cytokines, such as IL-31 and thymic stromal lymphopoietin (TSLP), were increased in AD skin lesions, administration of AMP-IBP5 decreased the expression of type 2 and pruritic cytokines (Figure 7A).